AstraZeneca PLC
AZN Healthcare Drug Manufacturers General
AstraZeneca PLC’s revenue for fiscal 2025 (year ended December 2025) was $58.7 billion, up 8.63% from fiscal 2024. In the quarter to June 2026, revenue grew 6.41%, EPS grew 1.90%, free cash flow fell 107.5% and total debt fell 5.50%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for five; insiders bought in the last twelve months.
Follow AZN
AstraZeneca PLC (AZN) EV/Sales
As of 9 October 2026, AstraZeneca PLC (AZN) trades at a EV/Sales of 4.4×. Over the past ten years it has ranged from 3.2× (March 2016) to 11.4× (February 2026); the current reading is higher than 25% of that period. That is above the Drug Manufacturers General industry median of 3.9× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 10.1× | 26.92% |
| FY2024 | 7.9× | 55.91% |
| FY2023 | 5.1× | (4.46%) |
| FY2022 | 5.3× | 5.81% |
| FY2021 | 5.0× | (6.05%) |
| FY2020 | 5.4× | (7.28%) |
| FY2019 | 5.8× | 16.77% |
| FY2018 | 5.0× | 8.24% |
| FY2017 | 4.6× | 29.98% |
| FY2016 | 3.5× | (7.48%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 5.2× | (4.88%) |
| Mar 2026 | 5.5× | (45.85%) |
| Dec 2025 | 10.1× | 124.73% |
| Sep 2025 | 4.5× | 5.29% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| BMY Bristol Myers Squibb Company compare | 3.1× |
| PFE Pfizer Inc. compare | 3.3× |
| NVO Novo Nordisk A/S compare | 3.6× |
| AZN AstraZeneca PLC | 4.4× |
| NVS Novartis AG compare | 5.5× |
| MRK Merck & Co., Inc. compare | 6.1× |
| GILD Gilead Sciences, Inc. compare | 6.9× |
| AMGN Amgen Inc. compare | 7.0× |
| ABBV AbbVie Inc. compare | 8.6× |
| Drug Manufacturers General industry median | 3.9× |
| Healthcare sector median | 3.6× |
| Market median | 2.2× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)